Exubera Adoption Not Recommended By U.K. Cost-Effectiveness Group
This article was originally published in The Pink Sheet Daily
Executive Summary
The National Institute for Health & Clinical Excellence says it needs more evidence on Pfizer’s inhaled insulin before it can recommend NHS coverage.
You may also be interested in...
Pfizer’s Exubera Receives Nicer Recommendations From U.K.’s NICE
The group recommends inhaled insulin for diabetes patients with problems finding injection sites and injection phobias.
Pfizer’s Exubera Receives Nicer Recommendations From U.K.’s NICE
The group recommends inhaled insulin for diabetes patients with problems finding injection sites and injection phobias.
Generic Competition May Have Taken A Bite Out Of Lipitor
The statin’s sales got off to a sluggish start in the first quarter but Pfizer maintains the drug will reach its $13 bil. revenue target for the year.